Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

A Review of Gaucher Disease in Korea

  • Sohn, Young Bae (Department of Medical Genetics, Ajou University Hospital, Ajou University School of Medicine)
  • Received : 2021.05.09
  • Accepted : 2021.06.05
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Gaucher disease (GD, OMIM #230800 OMIM#230800) is a rare, autosomal recessive inherited metabolic disorder caused by mutation in GBA1 encoding the lysosomal enzyme, glucocerebrosidase. The deficiency of glucocerebrosidase leads to an accumulation of its substrate, glucosylceramide in macrophages of various tissues. Common clinical manifestations include cytopenia, splenomegaly, hepatomegaly, and bone lesions. The phenotype of GD is classified into three clinical categories: Type 1 (non-neuronopathic) is characterized by involvements on the viscera, whereas types 2 and 3 (neuronopathic) are associated with not only visceral symptoms but also neurological impairment, either severe in type 2 or variable in type 3. A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes. Mutations in the GBA1 should be identified as they may be of prognostic value in some cases. Biomarkers including Chitotriosidase, CCL18, and glucosylsphingosine (lyso-GL1) are useful in diagnosis and treatment monitoring. Currently available disease-specific treatment in Korea consists of intravenous enzyme replacement therapy and substrate reduction therapy. For enhancing long-term prognosis, the onset of Parkinson's disease and Lewy body dementia, or the occurrence of a blood disease or cancer (hepatocellular carcinoma) should be monitored in older patients. The development of new strategies that can modify the neurological phenotype are expected, especially in Asia including Korea, where the prevalence of neuronopathic GD is relatively higher than that in western countries.

Keywords

References

  1. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372:1263-71. https://doi.org/10.1016/S0140-6736(08)61522-6
  2. Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 2011;46:11-4. https://doi.org/10.1016/j.bcmd.2010.07.010
  3. Lee RE. The fine structure of the cerebroside occurring in Gaucher's disease. Proc Natl Acad Sci U S A 1968;61:484-9. https://doi.org/10.1073/pnas.61.2.484
  4. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017;18:441-71. https://doi.org/10.3390/ijms18020441
  5. Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997;23:201-12. https://doi.org/10.1006/bcmd.1997.0137
  6. van Breemen MJ, de Fost M, Voerman JS, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 2007;1772:788-96. https://doi.org/10.1016/j.bbadis.2007.04.002
  7. Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 2010;107:19473-8. https://doi.org/10.1073/pnas.1003308107
  8. Dekker N, van Dussen L, Hollak CE, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011;118:e118-27. https://doi.org/10.1182/blood-2011-05-352971
  9. Mistry PK, Liu J, Sun L, et al. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A 2014;111:4934-9. https://doi.org/10.1073/pnas.1400768111
  10. Ron I, Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 2005;14:2387-98. https://doi.org/10.1093/hmg/ddi240
  11. Yang C, Wang H, Zhu D, et al. Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation. Proc Natl Acad Sci U S A 2015;112:1137-42. https://doi.org/10.1073/pnas.1424288112
  12. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8. https://doi.org/10.1001/archpedi.160.6.603
  13. Regenboog M, Bohte AE, Somers I, van Delden OM, Maas M, Hollak CE. Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease. Blood Cells Mol Dis 2016;60:49-57. https://doi.org/10.1016/j.bcmd.2016.06.009
  14. Taddei TH, Dziura J, Chen S, et al. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 2010;33:291-300. https://doi.org/10.1007/s10545-010-9070-1
  15. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75 Suppl 1:A2-12. https://doi.org/10.1259/bjr.75.suppl_1.750002
  16. Clarke LA, Hollak CE. The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders. Best Pract Res Clin Endocrinol Metab 2015;29:219-35. https://doi.org/10.1016/j.beem.2014.08.010
  17. Marcucci G, Zimran A, Bembi B, et al. Gaucher disease and bone manifestations. Calcif Tissue Int 2014;95:477-94. https://doi.org/10.1007/s00223-014-9923-y
  18. Yossipovitch ZH, Herman G, Makin M. Aseptic osteomyelitis in Gaucher's disease. Isr J Med Sci 1965;1:531-6.
  19. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-61. https://doi.org/10.1056/NEJMoa0901281
  20. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52. https://doi.org/10.1016/j.cell.2011.06.001
  21. Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014;71:752-7. https://doi.org/10.1001/jamaneurol.2014.313
  22. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 2010;33:167-73. https://doi.org/10.1007/s10545-010-9055-0
  23. Biegstraaten M, Mengel E, Marodi L, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010;133:2909-19. https://doi.org/10.1093/brain/awq198
  24. Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006;28:39-48. https://doi.org/10.1016/j.braindev.2005.04.005
  25. Mignot C, Gelot A, Bessieres B, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A 2003;120a:338-44. https://doi.org/10.1002/ajmg.a.20117
  26. Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 2010;33:339-46. https://doi.org/10.1007/s10545-009-9009-6
  27. George R, McMahon J, Lytle B, Clark B, Lichtin A. Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation. Clin Genet 2001;59:360-3. https://doi.org/10.1034/j.1399-0004.2001.590511.x
  28. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991;60:257-80. https://doi.org/10.1146/annurev.bi.60.070191.001353
  29. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 1989;4:87-96. https://doi.org/10.1016/0888-7543(89)90319-4
  30. Kim YM, Choi JH, Kim GH, et al. The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects. Orphanet J Rare Dis 2020;15:318. https://doi.org/10.1186/s13023-020-01597-0
  31. Aerts JM, Kallemeijn WW, Wegdam W, et al. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis 2011;34:605-19. https://doi.org/10.1007/s10545-011-9308-6
  32. Mekinian A, Stirnemann J, Belmatoug N, et al. Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment. Blood Cells Mol Dis 2012;49:53-7. https://doi.org/10.1016/j.bcmd.2012.04.002
  33. van Dussen L, Hendriks EJ, Groener JE, Boot RG, Hollak CE, Aerts JM. Value of plasma chitotriosidase to assess nonneuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J Inherit Metab Dis 2014;37:991-1001. https://doi.org/10.1007/s10545-014-9711-x
  34. Bussink AP, Verhoek M, Vreede J, et al. Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. Febs J 2009;276:5678-88. https://doi.org/10.1111/j.1742-4658.2009.07259.x
  35. Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005;35:259-67. https://doi.org/10.1016/j.bcmd.2005.05.005
  36. Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122:359-69. https://doi.org/10.1309/BG5V-A8JR-DQH1-M7HN
  37. Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a nonJewish, Caucasian cohort of Gaucher disease patients. PLoS One 2013;8:e79732. https://doi.org/10.1371/journal.pone.0079732
  38. Murugesan V, Chuang WL, Liu J, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol 2016;91:1082-9. https://doi.org/10.1002/ajh.24491
  39. Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105-10. https://doi.org/10.1097/01.gim.0000153660.88672.3c
  40. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-70. https://doi.org/10.1056/NEJM199105233242104
  41. Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010;116:893-9. https://doi.org/10.1182/blood.v116.21.893.893
  42. Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 2014;53:274-6. https://doi.org/10.1016/j.bcmd.2014.04.002
  43. Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. Jama 2015;313:695-706. https://doi.org/10.1001/jama.2015.459
  44. Belmatoug N, Di Rocco M, Fraga C, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med 2017;37:25-32. https://doi.org/10.1016/j.ejim.2016.07.011
  45. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014;99:392-8. https://doi.org/10.3324/haematol.2013.092460
  46. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31:319-36. https://doi.org/10.1007/s10545-008-0779-z
  47. Dunbar CE, Kohn DB, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998;9:2629-40. https://doi.org/10.1089/10430349850019463
  48. Dahl M, Doyle A, Olsson K, et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther 2015;23:835-844. https://doi.org/10.1038/mt.2015.16
  49. Sanchez-Martinez A, Beavan M, Gegg ME, Chau KY, Whitworth AJ, Schapira AH. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci Rep 2016;6:31380. https://doi.org/10.1038/srep31380
  50. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137(Pt 5):1481-95. https://doi.org/10.1093/brain/awu020